09/03/2018 02:07:36

Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results

Related content
11 Jun - 
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccin..
03 May - 
Vical Reports First Quarter 2018 Financial and Operatio..
02 May - 
Market Trends Toward New Normal in City Office REIT, Ma..

SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended December 31, 2017, before the opening of trading on Thursday, March 15, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, March 15. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on development programs in the conference call and webcast.

Conference Call

To listen to the conference call, dial in approximately ten minutes before the scheduled call to (323) 994-2083 (preferred), or (800) 562-8369 (toll-free), and reference confirmation code 2848082. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 2848082. The call also will be available live and archived through the events page at www.vical.com.

Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to ir@vical.com or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at ir@vical.com.

About Vical

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, including antiviral and antifungal candidates in clinical development. Additional information on Vical is available at www.vical.com.

Contact:         

Andrew Hopkins

(858) 646-1127

Website:  www.vical.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SHAREHOLDER ALERT: ALGT ESPR FLEX PPG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
2
Larson Electronics LLC Releases Explosion Proof Emergency LED Exit/KELUAR Sign
3
MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients
4
SeaBird Exploration Plc: SeaBird appoints new CEO
5
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care

Related stock quotes

Vical Incorporated 1.290 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 June 2018 08:54:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB2 - 2018-06-25 09:54:06 - 2018-06-25 08:54:06 - 1000 - Website: OKAY